Cytoreductive Surgery

CRS Fundamentals - Defining the Debulk

• CRS: Surgical removal of all visible tumor (peritoneal metastases).
• Aim: Maximal tumor debulking for optimal outcome.
• Significance: Enhances adjuvant therapy efficacy (e.g., HIPEC), ↑ survival.
• Completeness of Cytoreduction (CC) Score:
  • CC-0: No visible disease (Goal).
  • CC-1: Nodules < 2.5 mm.
  • CC-2: Nodules 2.5 mm-2.5 cm.
  • CC-3: Nodules > 2.5 cm.

⭐ Achieving CC-0 (no visible residual disease) in CRS is the most crucial factor for long-term survival.

Patient Selection - Who Gets CRS?

• Goal: Achieve complete cytoreduction (CC-0/CC-1).
• Key Considerations:
  • Good performance status (ECOG 0-1).
  • No major comorbidities precluding major surgery.
  • Disease biology: Low-grade tumors respond better.
  • Limited extra-peritoneal disease.
  • Possibility of achieving complete cytoreduction.

⭐ The Peritoneal Cancer Index (PCI) score is a critical preoperative assessment tool to quantify disease burden and determine resectability in peritoneal surface malignancies. A PCI score < 20 is often a favorable prognostic factor.

The CRS Procedure - Surgical Showdown

• Objective: Achieve complete macroscopic tumor removal.
• Core Components:
  • Peritonectomy: Removal of diseased peritoneum.
  • Visceral Resections: Targeted removal of involved organs (e.g., omentum, spleen, bowel segments).
• Completeness of Cytoreduction (CC) Score:
  • CC-0: No visible disease.
  • CC-1: Residual tumor < 2.5 mm.
  • CC-2: Residual tumor 2.5 mm - 2.5 cm.
  • CC-3: Residual tumor > 2.5 cm.

⭐ CC-0 (no macroscopic residual disease) is the single most important prognostic factor for survival in CRS patients.

HIPEC & Adjuvants - The Chemo Cocktail

• HIPEC (Hyperthermic Intraperitoneal Chemotherapy):
  • Heated chemo (e.g., Mitomycin C, Cisplatin, Oxaliplatin) circulated in peritoneum. 📌 My Cousin Owes.
  • Temperature: 41-43°C; Duration: 60-90 minutes.
  • Goal: Eradicate microscopic residual tumor cells post-CRS.
  • Mechanism: Hyperthermia ↑ drug penetration & cytotoxicity.
• Other Adjuvants:
  • EPIC: Early Postoperative Intraperitoneal Chemotherapy (non-heated).
  • NIPEC: Normothermic Intraperitoneal Chemotherapy.
  • Systemic Chemotherapy: Neoadjuvant or adjuvant.

⭐ Hyperthermia (typically 41-43°C) during HIPEC enhances the penetration and cytotoxic effect of chemotherapeutic agents like Mitomycin C or Cisplatin in the peritoneal cavity.

Outcomes & Complications - The Aftermath

• Outcomes:
  • ↑ Median survival & DFS in select patients (e.g., appendiceal, ovarian, mesothelioma).
  • Prognostic Factors:
    • Completeness of Cytoreduction (CC-0/1 ideal).
    • Peritoneal Cancer Index (PCI <20 is favorable).
    • Tumor histology, grade, & careful patient selection.
• Complications:
  • Morbidity: Significant, reported 30-50%; Mortality: <5% in experienced, high-volume centers.
  • Common: Anastomotic leak, prolonged ileus, infections (SSI, pneumonia), myelosuppression (esp. post-HIPEC), DVT/PE, fistulas.
  • Quality of Life (QoL): Initially ↓, typically improves over several months.

⭐ Major morbidity after CRS and HIPEC can be significant (up to 30-50%), with common complications including anastomotic leaks, infections, and myelosuppression; however, in experienced centers, mortality is <5%.

High‑Yield Points - ⚡ Biggest Takeaways

• CRS (Cytoreductive Surgery) targets no gross residual disease (CC-0) in peritoneal malignancies, often combined with HIPEC.
• Main indications: Appendiceal, colorectal, ovarian cancers, and peritoneal mesothelioma.
• Peritoneal Cancer Index (PCI) is vital for selection; PCI >20 often excludes patients.
• Completeness of Cytoreduction (CC score) is the strongest predictor of survival.
• HIPEC uses heated chemotherapy (e.g., Mitomycin C, Cisplatin) to target microscopic cells post-CRS.
• Associated with significant morbidity; requires specialized, high-volume centers for optimal outcomes.
• Sugarbaker's principles often guide the peritonectomy techniques employed during CRS.